INFORM ATION SHEE T FOR BUSINESS

PA RT NER S & DIS T RIBU TOR S

Summary of key studies and papers

Own studies and abstracts

Observational study of 100 patients from November 2011 to October 2014

ACRS vs. PRP Basic differences between PRP and ACRS (Sanakin Technology)

Detection of anti-inflammatory cytokines in ACRS (03-2022)

Sanakin scientific paper

Comprehensive introduction to the biological active principle of cytokines – the messenger substances of our immune
system. This paper describes how the positive cytokines work and how they enable the 100% autologous approach of the
Sanakin technology.

International key studies and papers on anti-inflammatory cytokines

1. Dinarello CA: Interleukin-1. Rev Infect Dis 1984; 6:51–95.
2. Arend WP, Joslin FG, Massoni RJ: Effects of immune complexes on production by human monocytes of interleukin 1
or an interleukin 1 inhibitor. J. Immunol 1985; 134:3868–75.
3. Dinarello CA, Thompson RC: Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today
1991;12: 404–10.
4. Arend WP, Smith MFJ, Janson RW, Joslin FG: IL-1 receptor antagonist and IL-1 beta production in human monocytes
are regulated differently. J. Immunol 1991; 147: 1530–6.
5. Arend WP, Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 139
(1994) 71–78.
6. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C et al: Chondroprotective effect of intraarticular
injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1
expression. Arthritis Rheum 39(1996)1535–1544.
7. Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P et al: Clinical trials in the gene therapy of
arthritis. Clin Orthop 379 (2000) Suppl, S300–307.
8. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, Mcliwraith: Treatment of experimental equine osteoarthritis by in
vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene therapy 9 (2002)12–20
9. Goldring MB: Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2 (2000) 459–465.
10. Goldring MB: Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 1(2001) 817–829.
11. Heilmann HH, Lindenhayn K, Walther HU: Synovial volume of healthy and arthrotic human kneejoints. Z Orthop Ihre
Grenzgeb 134 (1996) 144–148.
12. Moss SG, Schweitzer ME, Jacobson JA, Brossmann J, Lombardi JV, Dellose SM et al: Hip joint fluid: detection and
distribution at MR imaging and US with cadaveric correlation. Radiology 208 (1998) 43–48.
 INFORM ATION SHEE T FOR BUSINESS
PA RT NER S & DIS T RIBU TOR S

13. Neidel J, Schulze M, Sova L, Lindschau J: Practical significance of cytokine determination in joint fluid in patients with
arthroses or rheumatoid arthritis. Z Orthop Ihre Grenzgeb 134 (1996) 381–385.
14. Pelletier JP, Caron JP, Evans CH, Robbins PD, Georgescu HI, Jovanovic D et al: In vivo suppression of early experimen-
tal osteoarthritis by interleukin1 receptor antagonist using gene therapy. Arthritis Rheum 40 (1997) 1012–1019.
15. Firestein GS, Alvaro-Gracia JM, Maki R.: Quantitative analysis of cytokine gene expression in rheumatoid arthritis.
Published erratum appears in J. Immunol 1990 Aug. 1; 145(3): 10371. J. Immunol 1990; 144: 3347–53.
16. Granowitz EV, Clark BD, Mancilla J, Dinarello CA: Interleukin-1 receptor antagonist competitively inhibits the binding
of interleukin-1 to the type II interleukin-1 receptor. J. Biol Chem 1991; 266: 14147–50
17. Arend WP et al.: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27–55
18. Gabay C, Arend WP (1998): Treatment of rheumatoid arthritis with IL-1 inhibitors. Semin Immunopathol 20(1-2): 229–246
19. Van den Berg WB et al. (1991): In vivo evidence for a key< role of IL-1 in cartilage destruction in experimental
arthritis. Agents Actions 32 (suppl): 159–163
20. Towle CA et al. (1997): Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/ paracrine
role in pathogenesis. Osteoarthr Cartil 5(5): 293–300

Recent studies and papers (2017 — 2022)

1. K. Shirokova, S. Noskov, L. Shirokova: Comparison of clinical efficacy of platelet-rich plasma and autologous
conditioned serum treatment in patients with osteoarthritis of the knee: 2017; DOI: https://doi.org/10.1016/j.
joca.2017.02.756
2. Lilian SOLE et al. Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of
Efficacy Than Other Kinds of Platelet-Rich Plasma; 2019; https://acrabstracts.org/abstract/autologous-conditioned-
serum-and-plasma-rich-in-growth-factors-show-stronger-evidence-of-efficacy-than-other-kinds-of-platelet-rich-
plasma/
3. Hüseyin Sina Coşkun, Alparslan Yurtbay, Ferhat Say: Platelet Rich Plasma Versus Autologous Conditioned Serum
in Osteoarthritis of the Knee: Clinical Results of a Five-Year Retrospective Study; 2022; https://pubmed.ncbi.nlm.nih.
gov/35651374/)
4. Duan, Weifeng MD et  al. No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function
in Patients with Hemophilic Knee Arthritis: A Randomized Trial; 2022; https://journals.lww.com/clinorthop
toc/2022/12000
5. Gokay Baykara et al. Autologous Conditioned Serum Increases Fat Graft Viability More than Platelet-Rich Plasma in a
Controlled Rat Model; 2022; https://pubmed.ncbi.nlm.nih.gov/35271553/

Recent studies and papers (2017 — 2022)

1. ACRS in IVF (In Vitro fertilization): Case studies in a chain of hospitals in north India by Ms. Nita
2. ACRS in ophthalmology: Case study in the Sankara Nethralaya Eye Hospital, Chennai, India
3. Application of ACRS in erectile dysfunction: University Medical Center Freiburg, Germany
4. ACRS in wound healing: Ludwig Maximilian University of Munich, Germany

Many more scientific information available in our Service Portal my.sanakin.com

Shared experience of HCPs globally on Social Media like Instragram, Facebook, etc. #Sanakin